European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a special purpose acquisition company that completed its IPO in 2021, targeting opportunities in the European life sciences and biotechnology sector. Sponsored by EBAC Sponsor LLC, the company filed a definitive merger proxy statement on Form DEFM14A on February 3, 2023, a filing that signals the SPAC had reached a definitive business combination agreement and was advancing toward a shareholder vote to approve the transaction. EBAC sits at an active deal stage within the healthcare and life sciences industry, reflecting continued SPAC activity in the European biotech space. Sign up on SpacDesk for full filing history, deal timelines, and analytics on EBAC and hundreds of other SPACs.